<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088750</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000667369</org_study_id>
    <secondary_id>2007-004092-19</secondary_id>
    <nct_id>NCT01088750</nct_id>
  </id_info>
  <brief_title>Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma</brief_title>
  <acronym>EuroNetLP1</acronym>
  <official_title>First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Mauz-Körholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Euronet Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, vinblastine, and&#xD;
      prednisolone, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Surgery to remove involved lymph nodes may be an&#xD;
      effective treatment for young patients with nodular lymphocyte-predominant Hodgkin lymphoma.&#xD;
&#xD;
      PURPOSE: This phase IV trial is continuing to study the side effects of giving surgery alone&#xD;
      or giving surgery with cyclophosphamide, vinblastine, and prednisolone compared with giving&#xD;
      cyclophosphamide, vinblastine, and prednisolone alone in treating young patients with stage&#xD;
      IA or stage IIA nodular lymphocyte-predominant Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the 5-year event-free survival of children or adolescents with stage IA or IIA&#xD;
           nodular lymphocyte-predominant Hodgkin lymphoma treated with surgery alone or with&#xD;
           cyclophosphamide, vinblastine, and prednisolone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine if this regimen results in a decrease in overall survival rates, in&#xD;
           significant upstaging at relapse, or increased rates of histological transformation in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Group 1 (patients with stage IA disease only): Patients undergo surgical resection of&#xD;
           the involved lymph nodes. Patients who achieve complete resection then enter follow-up&#xD;
           (watch and wait); patients who do not achieve complete resection enters group 2&#xD;
           treatment.&#xD;
&#xD;
        -  Group 2 (patients with stage IIA disease or incompletely resected stage IA disease):&#xD;
           Patients receive cyclophosphamide, vinblastine, and prednisolone for 3 courses. Patients&#xD;
           with good response enter follow-up (watch and wait). Patients without a good response&#xD;
           are taken off protocol.&#xD;
&#xD;
      After completion of study treatment, patients are followed-up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2009</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from treatment start until relapse/progression, secondary malignancy or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant upstaging at relapse defined as development of B-symptoms, extranodal disease, or relapse higher than stage II</measure>
    <time_frame>5 years</time_frame>
    <description>Stage greater than IIA at relapse diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from treatment start until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Toxicity criteria toxicity Levels of therapy elements</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of AEs, SAEs atc. according to CTC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgery</measure>
    <time_frame>5 years</time_frame>
    <description>Listing of surgical complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>surgery alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVP Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>CVP Chemotherapy</arm_group_label>
    <other_name>CYC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>CVP Chemotherapy</arm_group_label>
    <other_name>PRED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
    <arm_group_label>CVP Chemotherapy</arm_group_label>
    <other_name>VBL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>watchful waiting</intervention_name>
    <arm_group_label>surgery alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>surgery alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology.&#xD;
&#xD;
          -  initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and&#xD;
             residual tumour after relapse biopsy and no additional surgery planned in nLP patients&#xD;
             relapsing after surgery alone&#xD;
&#xD;
          -  patient aged under 18 years at time of diagnosis&#xD;
&#xD;
          -  written informed consent of the patient and/or the patient's parents or guardian&#xD;
             according to national laws&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  pre-treatment of Hodgkin's lymphoma differing from study protocol&#xD;
&#xD;
          -  Any extra-nodal involvement&#xD;
&#xD;
          -  Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging&#xD;
             and response assessment&#xD;
&#xD;
          -  known hypersensitivity or contraindication to study drugs&#xD;
&#xD;
          -  prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  Current or recent therapy (within 30 days prior to the start of trial treatment) with&#xD;
             steroids&#xD;
&#xD;
          -  Current or recent (within 30 days prior to the start of trial treatment) treatment&#xD;
             with another investigational drug or participation in another investigational trial&#xD;
&#xD;
          -  other (simultaneous) malignancies&#xD;
&#xD;
          -  severe concomitant diseases (e.g. immune deficiency syndrome)&#xD;
&#xD;
          -  known HIV positivity&#xD;
&#xD;
          -  pregnancy and / or lactation&#xD;
&#xD;
          -  females who are sexually active refusing to use effective contraception (oral&#xD;
             contraception, intrauterine devices, barrier method of contraception in conjunction&#xD;
             with spermicidal jelly or surgical sterile) (except for surgery only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum Giessen und Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen-Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?a=8&amp;id=NCI-2014-02026&amp;loc=0&amp;rl=2&amp;st=C7258&amp;t=C9357</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christine Mauz-Körholz</investigator_full_name>
    <investigator_title>Prof. Dr. Christine Mauz-Körholz</investigator_title>
  </responsible_party>
  <keyword>childhood nodular lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

